Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Use and effectiveness of transdermal nicotine in primary care settings.

Cummings KM, Biernbaum RM, Zevon MA, Deloughry T, Jaén CR.

Arch Fam Med. 1994 Aug;3(8):682-9.

PMID:
7952254
2.
3.

Community patterns of transdermal nicotine use and provider counseling.

Swartz SH, Ellsworth AJ, Curry SJ, Boyko EJ.

J Gen Intern Med. 1995 Dec;10(12):656-62.

PMID:
8770717
4.

Smoking cessation: a clinical study of the transdermal nicotine patch.

Smith TM, Winters FD.

J Am Osteopath Assoc. 1995 Nov;95(11):655-6, 661-2.

PMID:
8575948
6.

Transdermal nicotine patches with low-intensity support to aid smoking cessation in outpatients in a general hospital. A placebo-controlled trial.

Foulds J, Stapleton J, Hayward M, Russell MA, Feyerabend C, Fleming T, Costello J.

Arch Fam Med. 1993 Apr;2(4):417-23. Review.

PMID:
8130921
7.

The transdermal nicotine patch: results of a randomised placebo-controlled trial.

Richmond RL, Harris K, de Almeida Neto A.

Med J Aust. 1994 Jul 18;161(2):130-5.

PMID:
8028537
8.

Characteristics and perceptions of nicotine patch users.

Haxby D, Sinclair A, Eiff MP, McQueen MH, Toffler WL.

J Fam Pract. 1994 May;38(5):459-64.

PMID:
8176343
9.

High dose transdermal nicotine therapy for heavy smokers: safety, tolerability and measurement of nicotine and cotinine levels.

Fredrickson PA, Hurt RD, Lee GM, Wingender L, Croghan IT, Lauger G, Gomez-Dahl L, Offord KP.

Psychopharmacology (Berl). 1995 Dec;122(3):215-22.

PMID:
8748390
10.

Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling.

Sachs DP, Säwe U, Leischow SJ.

Arch Intern Med. 1993 Aug 23;153(16):1881-90. Erratum in: Arch Intern Med 1993 Oct 25;153(20):2321.

PMID:
8110249
11.

A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations.

Robles GI, Singh-Franco D, Ghin HL.

Clin Ther. 2008 May;30(5):800-12. doi: 10.1016/j.clinthera.2008.05.010. Review.

PMID:
18555928
12.

Application of serum nicotine and plasma cotinine concentrations to assessment of nicotine replacement in light, moderate, and heavy smokers undergoing transdermal therapy.

Lawson GM, Hurt RD, Dale LC, Offord KP, Croghan IT, Schroeder DR, Jiang NS.

J Clin Pharmacol. 1998 Jun;38(6):502-9.

PMID:
9650539
13.

Triple-combination pharmacotherapy for medically ill smokers: a randomized trial.

Steinberg MB, Greenhaus S, Schmelzer AC, Bover MT, Foulds J, Hoover DR, Carson JL.

Ann Intern Med. 2009 Apr 7;150(7):447-54.

PMID:
19349630
14.

Comparative efficacy of 24-hour and 16-hour transdermal nicotine patches for relief of morning craving.

Shiffman S, Elash CA, Paton SM, Gwaltney CJ, Paty JA, Clark DB, Liu KS, Di Marino ME.

Addiction. 2000 Aug;95(8):1185-95.

PMID:
11092066
15.

Efficacy and safety of an over-the-counter transdermal nicotine patch as an aid for smoking cessation.

Davidson M, Epstein M, Burt R, Schaefer C, Whitworth G, McDonald A.

Arch Fam Med. 1998 Nov-Dec;7(6):569-74.

PMID:
9821833
16.

Use of the nicotine skin patch by smokers in 20 communities in the United States, 1992-1993.

Cummings KM, Hyland A, Ockene JK, Hymowitz N, Manley M.

Tob Control. 1997;6 Suppl 2:S63-70.

17.

Transdermal nicotine replacement for hospitalized patients: a randomized clinical trial.

Lewis SF, Piasecki TM, Fiore MC, Anderson JE, Baker TB.

Prev Med. 1998 Mar-Apr;27(2):296-303.

PMID:
9579010
19.

The use of nicotine replacement therapy during hospitalization.

Emmons KM, Goldstein MG, Roberts M, Cargill B, Sherman CB, Millman R, Brown R, Abrams DB.

Ann Behav Med. 2000 Fall;22(4):325-9.

PMID:
11253444
20.

Physicians' counseling of patients when prescribing nicotine replacement therapy.

Shiffman S, Ferguson SG, Hellebusch SJ.

Addict Behav. 2007 Apr;32(4):728-39.

PMID:
16875786
Items per page

Supplemental Content

Support Center